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Rheumatoid arthritis (RA) is a common worldwide chronic autoimmune disease, characterised by synovial
hyperplasia, inflammatory cell infiltration, pannus formation and destruction of articular cartilage and bone
matrix. It is one of the most common forms of osteoarthritis bestowing high rates of both disability and
death. Increasing attention has been paid to the use of natural medicines and natural products in the
treatment of RA and patients' acceptance has increased year by year because of their high efficacy and
safety. Flavonoids are a group of important secondary metabolites occurring in many plants which have
rich biological activities such as anti-rheumatic, vasodilator, and anti-tumor effects. Many successful
medical treatments of RA appear to be attributable to the application of flavonoids. Quercetin,
a representative active member of the flavonoid family, is found abundantly in many plants, e.g. apples,
berries, cabbages, onions, and ginkgo. In recent years, progress has been made in the research of its
anti-rheumatoid effects which indicate that it is potentially a noteworthy prodrug for the treatment of
RA. However, the poor solubility of quercetin affects its bioavailability and clinical efficacy. This review
aims to provide an up to date summary of the biological effects and mechanism of action of quercetin
for the treatment of RA, and the research progress made towards nano formulations of quercetin to
improve its solubility and efficacy.r Feng Guan majored in
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1 Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease,
characterised by synovial hyperplasia, inammatory cell inl-
tration, pannus formation and destruction of articular cartilage
and bone matrix.1 It is one of the most common and disabling
forms of osteoarthritis. It is mainly manifested by redness,
swelling, a hot sensation, pain, and other symptoms of theDr Qi Wang majored in nano-
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University of East Anglia. She
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associate. She has extensive
experience in design, fabrication
and pre-clinical validation of
multifunctional nano drug
delivery system. Her research
interests are developing novel
nanomaterials for cancer imaging and treatment, studying the
interactions between nanomaterials and biological system, and
phytochemical nanoformulation for cancer prevention and
therapy.


























































































View Article Onlinesmall joints of the extremities. The lesions develop symmetri-
cally and destructively, which may eventually lead to joint
deformity and loss of function, and can even affect the heart,
lungs and nervous system.2,3 In most developed countries, RA
affects 0.3–1.0% of the adult population.4,5 At present, steroidal,
non-steroidal anti-inammatory drugs (NSAIDs), disease
modifying anti-rheumatic drugs (DMARDs), glucocorticoids,
bacterial therapy6 and targeted treatment7 are used to relieve
pain and control the disease. Patients with severe joint
involvement may suffer disability, and may even require joint
repair or replacement.8,9
However, long-term administration of these drugs may cause
gastrointestinal discomfort, nausea, vomiting, and bleeding, or
other adverse reactions such as to the central nervous system or
cardiovascular system. Moreover, improper application of
hormones may even aggravate the disease. When the disease is
difficult to control, biological agents such as tumour necrosis
factor inhibitors, abatacept, rituximab, and tocilizumab are
oen used in clinic. However their use is limited by high cost
and adverse events i.e. reactions and infections at infusion and
injection sites.4 Increasing attention has been paid to the use of
natural medicines or natural products in the treatment of RA,
and the patients' acceptance has increased year by year because
of their high efficacy and safety.
The avonoids are vital secondary metabolites of many
plants with the basic structural skeleton of 2-phenyl chromo-
genic ketone and consist of C6–C3–C6. It is a polyphenolic
compound comprising two aromatic rings (A and B) and
a heterocyclic ring (C). There are some avonoid compounds
that have a three-carbon chain but without a ring C. Some
avonoids exist in the form of dimers, trimers and even thio-
avones. The main classes of natural avonoids are avones,
isoavones, avanols, dihydroavones, dihydroavanols, bio-
avonoids, triavonoids, thioavones, etc. (Fig. 1). Flavonoids
have a number of biological activities (Fig. 2) including anti-
inammatory, analgesic, anti-rheumatic, vasodilator, anti-Yongping Bao is Reader in
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© 2021 The Author(s). Published by the Royal Society of Chemistryaging, and anti-tumour effects.10,11 The success of many
medical treatments can be attributed to the application of
avonoids and new scientic studies of these compounds and
their derivatives have focused on the activities above.12,13
Quercetin (5,7,30,40-tetrahydroxyavonol, C15H10O7) is
a representative member of the avonoid's family. It is found
abundantly in a variety of foods including apples, berries,
Brassica vegetables, grapes, onions, shallots, as well as many
medicinal plants including Ginkgo biloba, Hypericum perfo-
ratum, and Sambucus canadensis.14–16 Quercetin frequently
occurs as quercetin glycosides where polyhydroxyl substitution
appears in its structure.17 The quercetin glycosides derivatives that
have been identied include quercetin-3-O-rhamnoside (querci-
trin), quercetin-3-O-glycoside (isoquercitrin), quercetin-3-O-rutino-
side (rutin), and quercetin-7-O-glycoside (quercimeritrin)
(Fig. 3).18–20Quercetin possesses the typical pharmacological effects
of avonoids, such as anti-inammatory, analgesic, anti-
rheumatic, antioxidant, anti-tumour, etc.12,21–24. In recent years,
new progress has beenmade in the research of its anti-rheumatoid
effects which indicate that it is safe to use, with few side effects and
thus a noteworthy prodrug for the treatment of RA.
Despite showing promising potential for medicinal use, the
real-life application of quercetin has been largely limited due to
its poor solubility and bioavailability.13,18 The solubility of
quercetin in water is 7 mg mL1, and it is absorbed and
metabolised rapidly aer entering the body. Quercetin has
strong rst pass effect and its bioavailability is very low, less
than 3.6%. Quercetin is inactivated by combining with sugar
molecules into gluconic acid and so on. Therefore, there is
a need to employ modern nanotechnology to improve its solu-
bility and bioavailability, so as to better deploy its anti-
rheumatoid effects. This review is intended to provide an
insight into the pharmacological function and mechanisms of
action of therapeutic use of quercetin for RA. The recent
research progress using nano formulation as a strategy to
increase/improve quercetin potential in RA treatment have alsoDr Yimin Chao was appointed as
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View Article Onlinebeen summarised. Our review is mainly based on the published
journal papers in recent 15 years, excluding patent literature.2 Anti-rheumatic effects of quercetin
The pathogenesis of RA is complex and has not been fully
determined.25 Clinical treatment is mainly based on the
purpose of reducing inammation and alleviating symptoms.
There is considerable research interest in the potential health
benets of quercetin. Therefore, the anti-rheumatoid effect of
quercetin is summarised from the perspective of anti-
inammatory effects, analgesic effects, and the effect on
experimental rheumatoid animal models.Fig. 2 The main biological activities of flavonoids.
7282 | RSC Adv., 2021, 11, 7280–72932.1 Anti-inammatory effect and mechanism of action
Inammation plays a key role in rheumatoid diseases.26
Research results using both in vitro and animal models have
shown that quercetin can inhibit the occurrence and develop-
ment of inammation, thus having an important potential
impact on RA.
Liao and Lin studied the pharmacological effects of quer-
cetin on systemic inammation in septic mice.27 The sepsis
mouse model was established by intraperitoneally (i.p.) inject-
ing lipopolysaccharide (LPS). LPS is an important trigger of
inammatory response, which can stimulate a variety of cells in
vivo, especially macrophages to synthesize and release many
endogenous bioactive factors, leading to inammatory© 2021 The Author(s). Published by the Royal Society of Chemistry


























































































View Article Onlineresponse. They then administered quercetin to the septic mice
in a prophylactic or therapeutic manner. Their results sug-
gested that quercetin administration i.p. at a high dose of 0.15
mmol to each mouse could signicantly (P < 0.05) increase
Interleukin 10 (IL-10) secretion and had strong anti-
inammatory potential. Huang et al. similarly observed the
anti-inammatory effect of quercetin.28 Their results showed
that quercetin at 100, 200, and 400 mg kg1 could signicantly
inhibit the auricle swelling of rats caused by xylol, and the
degree of swelling and inhibition rate were signicantly
different from those in the control group (P < 0.01). This
suggests that quercetin can have a good inhibitory effect on
inammatory response.
RAW264.7 is a monocyte/macrophage-like cell line that has
been frequently used to study immune function. Zhou et al.
proved that quercetin signicantly inhibited the increase of
nitric oxide (NO), Tumour Necrosis Factor alpha (TNF-a),
Interleukin 18 (IL-18) and Interleukin 6 (IL-6) in Raw264.7 cells
induced by LPS (P < 0.01) showing that it has a good anti-
inammatory effect in vitro.29 These results agreed with the
ndings from Paul et al.30 and Cessak et al.31 which suggested
that quercetin is an effective inhibitor for TNF-a and IL-6. Ren
et al. also studied the protective effect of quercetin on LPS
induced inammation in RAW264.7 cells.32 Their results sug-
gested that the protective effect may be related to the regulation
of Toll-like receptor 4/nuclear factor kappa-light-chain-
enhancer of activated B (TLR4/NF-kB) signalling pathway.
Chronic inammation, a process linked to increased oxida-
tive stress, may inducemany diseases. Yeh et al. investigated the
effects of b-carotene on the inammatory reaction of macro-
phage model cells (differentiated HL-60 cells and RAW264.7
cells) and their modulation by quercetin or naringenin.33 Their
results demonstrated that quercetin partially suppressed the
pro-inammatory effects, synergistically enhanced the inhibi-
tory effects of b-carotene on the secretion of pro-inammatory© 2021 The Author(s). Published by the Royal Society of Chemistrymediators and the DNA damaging ability of PMA-stimulated HL-
60 cells. The mechanism of action was associated with its antiox-
idant activity and inhibition of the production of pro-inammatory
cytokines. Avila et al. summarised that quercetin showed a mixed
inhibition mechanism towards Adenosine triphosphate (ATP) and
that the binding site of quercetin overlaps with both ATP and
inhibitor of nuclear factor kappa B (IkBa) binding sites.34
Extracellular High-Mobility Group Box-1 (HMGB-1) is an impor-
tant late-stage inammatory transmitter with strong inammatory
activity. It contributes to the pathogenesis of numerous chronic
inammatory and autoimmune diseases including RA. Musumeci
et al. indicated that quercetin was a HMGB1 inhibitor and it could
limit the activation of mitogen-activated protein kinase.352.2 Analgesic effect and mechanism of action
In addition to its signicant anti-inammatory effect, quercetin
also shows signicant analgesic activity.
Liu DN has reported that quercetin had no signicant effect
on paw withdrawal thermal latency in näıve rats. However, it
could signicantly increase the threshold of mechanical paw
contraction response.36 The study also showed that quercetin has
a signicant inhibitory effect on bee venom induced spontaneous
nociceptive response, pain score, thermal and mechanical pain
sensitivity, and also on bee venom induced local inammatory
response.36 This suggests that quercetin's analgesic effect may be
related to the blocking of pro-inammatory factors. In addition,
quercetin has a considerable inhibitory effect on the ipsilateral
mechanical hyperalgesia and contralateral mechanical hyper-
algesia caused by sciatic nerve branch injury model.
In addition to the above studies on the anti-inammatory
and analgesic effects of quercetin monomer, there are also
a number related studies of medicinal plant extracts with
quercetin as the main component, which further conrm the


























































































View Article Online2.3 Effects on experimental animal model
There is growing interest in the anti-rheumatoid effects of
quercetin. The commonly used animal models of RA mainly
include adjuvant induced arthritis (AA), collagen induced
arthritis (CIA), oil induced arthritis (OIA), and proteoglycan
induced arthritis (PGIA).48–51 In recent years, the research of
anti-rheumatoid effect of quercetin has been mainly based on
AA and CIA models.
2.3.1 Effects on AA model. Guardia et al. studied anti-
inammatory effects of quercetin on adjuvant arthritis in rat
using the Mizushima et al. model of acute and chronic
inammation.52 The results showed that quercetin could
decrease the edema produced in the acute phase, induced 3–5 h
aer carrageenan injection (day 6). The reduction of paw
volume was from 53% to 47%. However, subsequently in the
chronic phase (day 7–30), quercetin had no signicant effects.
Mamani-Matsuda et al. observed that the therapeutic and
preventive properties of quercetin in experimental arthritis
correlated with decreased macrophage inammatory media-
tors.53 Their results indicated that in chronic rat (AA), oral
administration of quercetin (30mg per rat every 2 days, for 10 days)
to arthritic rats resulted in a clear decrease of clinical signs
compared to untreated controls. The effects of oral administration
of quercetin (150 mg kg1 daily, 28 days) were also investigated in
a rat model of adjuvant arthritis by Gardi et al.54. Their results
indicated that quercetin lowered levels of Interleukin 1b (IL-1b) (p <
0.003), monocyte chemotactic protein-1 (MCP-1) (p < 0.014) and
restored plasma antioxidant capacity.
2.3.2 Effects on CIA model. The anti-inammatory and
joint-protective properties of quercetin were studied using
a C57BL/6 CIA model by Haleagrahara et al.55. This study
determined that quercetin, which was non-toxic, produced
better results than methotrexate for the protection of joints
from arthritic inammation in mice. Yang et al. also reported
on the anti-rheumatoid effect of quercetin based on a CIA
model.56 The results showed that quercetin could attenuate the
CIAmodel viamodulating the T follicular helper 17/regulatory T
(Th17/Treg) balance, inhibiting NOD-like receptor protein 3
(NLRP3) inammasome activation as well as activating Heme
oxygenase-1 (HO-1)-mediated anti-inammatory response.
Wang et al. established a CIA model and investigated the effect
of quercetin on NF-kB activity and on the degradation of
chondrocyte matrix and apoptosis in rats with RA57 and showed
that quercetin could protect cartilage by inhibiting NF-kB acti-
vation, reducing Matrix metalloproteinase 13 (MMP-13)
production, matrix degradation and apoptosis in chon-
drocytes under inammatory environment. Jia et al. conrmed
that quercetin could signicantly relieve the arthritis index and
paw swelling of CIA mice58 and they also reported that quercetin
could effectively reduce the expression of inammatory factors
and matrix metalloproteinases in rheumatoid arthritis
broblast-like synoviocytes (RAFLS).59
2.3.3 Effect on zymosan induced RA models. The intra-
articular administration of zymosan is an experimental model
that promotes inammatory parameters resembling RA. Gua-
zelli et al. indicated that treatment with quercetin dose-7284 | RSC Adv., 2021, 11, 7280–7293dependently could reduce zymosan-induced hyperalgesia,
articular edema and the recruitment of neutrophils to the knee
joint cavity.60
2.3.4 Other effects. Quercetin has also been reported to
inhibit the activity of vascular endothelial growth factor (VEGF),
basic broblast growth factor (bFGF), matrix metalloproteinase-
2 (MMP-2) and other cytokines, inhibit angiogenesis and
synovial pannus formation. It is suggested that quercetin, plays
a role in counteracting RA inammation, and thus may be
reasonably proposed as an adjuvant drug for RA treatment.61
Xiao et al. collected synovial tissue samples from patients with
RA and proved that quercetin can affect the apoptosis of RAFLS
by regulating the expression of B-cell lymphoma 2 (Bcl-2) and
Bcl-2-associated X protein (Bax). With increasing quercetin
concentration, the Bcl-2/Bax value decreases correspondingly,
and the apoptosis rate of RAFLS increases.62 Furthermore, it has
been reported that quercetin can prevent boss loss, so has great
potential to be used as a bone health supplement.63,64 Quercetin
is a potential bioavailability enhancer that could improve the
bioavailability of other anti-rheumatoid drugs and play
a collaborative role.65 There are also some other studies
demonstrating the anti-rheumatoid effect of medicinal plant
extracts with quercetin as the main component.62,66–71 The anti-
rheumatoid effect of quercetin has been conrmed and the
overall research is summarised in Table 1.
2.4 Quercetin in vivo metabolism
Metabolism of absorbed avonoids including quercetin
involves their conjugation with glucuronide, sulfate and/or to
a limited extent, methylation of the catechol group.72 Glucur-
onidation requires uridine diphosphate glucuronosyltransfer-
ase (UDP-GT) and sulfation is dependent on sulfotransferase
activity. In general, the major metabolites of quercetin have less
bioactivity in comparison to the aglycone, however, there are
exceptions in that metabolites may have greater effects e.g. the
inhibitor constant Ki for the inhibition of xanthine oxidase by
quercetin glucuronides followed the order 40- > 30- > 7- > 3-, with
quercetin-40-glucuronide a particularly potent inhibitor (Ki ¼
0.25 mM; quercetin Ki ¼ 0.2 mM).72 Quercetin 3-glucuronide, and
30-methylquercetin 3-glucuronide from 0.1–1 mM inhibited
cyclooxygenase-2 (COX-2) expression in lymphocytes ex vivo in
a dose-dependent manner. However, a single high dose of
quercetin (4 mM) does not change COX-2 mRNA expression in
human lymphocytes in vivo.73 To date, a search on avonoids/
quercetin and Arthritis (Rheumatoid) in www.clinicaltrils.gov
showed no results.
3 Promotion of quercetin
pharmaceutical application by nano
formulation
Quercetin, as a potential anti rheumatoid drug, is of increasing
interest to the pharmaceutical industry. However, its low
hydrophilicity and lipophilicity limits its application. Further-
more, it is easily oxidised, and is sensitive to light and



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































View Article Onlinebioavailability, quite a few researches have been carried out.74–76
Among them, the application of nano technology provides
promise for the further development and utilization of quer-
cetin.77 Nanobiotechnology has been recently regarded as
a strategy to improve therapy efficacy by promoting the accu-
mulation of hydrophobic bioactive compounds in tissues.78,79 In
view of the current research progress, nano formulation of
quercetin can improve its solubility, and enhance its bioavail-
ability. At the same time, quercetin nanoparticles can also
change the way it is used in medication, control its release rate,
and reduce its side effects.
3.1 Nano formulation strategies
There has been an increasing focus on the drug delivery
potential of nano-formulations in the recent years.80–84 Appli-
cation of nano formulation strategies on bioactive molecules
could increase their solubility, absorption, bioavailability,
protect them from degradation, prolong their circulation time
in plasma,82,85 and make them selective biodistribution in the
inammatory parts.86 In addition, the nano formulation strat-
egies could also improve intracellular penetration, reduce
systemic toxicity and open up the potential for co-delivery of
therapeutic agents.87–89 Currently, many nano formulated
systems designed for therapeutic use of phytochemicals have
reached the clinical trial stage and are increasingly applied in
clinical practice.90,91 So far, a wide variety of nano formulation
systems have been used for pharmaceutical applications of
quercetin. There are organic92,93 and inorganic nano-
particles,94,95 nanomicelles,96,97 nanoliposomes,78 nano-
emulsions98 and nanocapsules99 all gathering great interest.
Nanoparticles for delivery of quercetin are generally with
a diameter of 20–200 nm. They are formulated using different
organic and inorganic materials including dietary bre,92
lactoglobulin,93 zein,100 casein,101 silica,94 and quantum dots.102
Nanomicelles are self-assembling nanosized colloidal disper-
sions consist of a hydrophobic core and hydrophilic shell.103
Amphiphilic materials are used to synthesise nanomicelles for
solubilising hydrophobic biomolecules like quercetin. Nano-
emulsions are nanosized emulsions in the range of 20–200 nm,
which prepared by either chemical or mechanical methods
using mixtures of immiscible liquids, such as water and oil.104
Nanoliposomes represent nanosized self-assembled lipid vesi-
cles with a structure of phospholipid bilayers entrapping one or
more therapeutic agents.105 Detailed applications of different
nano-formulations of quercetin on RA treatment are described
and discussed in the following sections.
3.2 Improvement of solubility
Kakran et al. prepared quercetin nanoparticles by evaporation
and precipitation nano-suspension (EPN). They studied the type
of antisolvent (e.g., water), the effect of concentration and the
ratio of solvent to antisolvent of quercetin particles formed in
the EPN process. It showed that the solid dispersion signi-
cantly improved quercetin solubility.106 According to the
experiment, quercetin showed a very low dissolution rate with
only 10% dissolved within 120 min. For the quercetin7286 | RSC Adv., 2021, 11, 7280–7293nanoparticles, the dissolution rate improved signicantly to
about 75% at 120 min. It can also be observed that relative
dissolution (RD) for quercetin nanoparticles was 7.69 at
120 min, and the time for 50% dissolution was only 7.9 min
compared to more than 120 min for quercetin. Moreover, they
reported that the size of quercetin nanoparticles was affected by
drug concentration, solvent to anti-solvent (S/AS) ratio, stirring
speed and ow rate.107 The results indicated that the dissolution
of quercetin nanoparticles was signicantly higher compared
with quercetin in simulated intestinal uid.
In the studies of Khor et al., quercetin was co-precipitated
with dietary bres into a fast-dissolving nano formulation via
antisolvent precipitation. It was found that a high dissolution
rate and good storage stability was achieved for quercetin nano
formulations with cellulose bre, resistant starch, or resistant
maltodextrin. The nano formulations exhibited higher levels of
antioxidant activities in contrast to quercetin alone.92
Garćıa-Casas et al. reported that a supercritical antisolvent
(SAS) process had been used to precipitate microparticles of
quercetin together with nanoparticles of cellulose acetate
phthalate (CAP). Release proles of quercetin were carried out
in simulated gastric and intestinal uids. Higher ratios of
quercetin to polymer in the coprecipitates were recommended
to achieve faster release and higher solubilities of quercetin.109
Wang et al. reported that amphiphilic chitosan was obtained
through graing of deoxycholic acid modied chitosan and N-
acetyl-L-cysteine. Quercetin-loaded nanomicelles (CS-DA-NAC-
QNMs) were prepared through a self-assembly method by
using amphiphilic chitosan as the wall-material and quercetin
as core-material. They demonstrated that there was a bursting
release of quercetin from CS-DA-NAC-QNMs for 0 to 8 hours,
and then the release rate decreased gradually. Aer 72 hours,
more than 40% of quercetin were released. All the quercetin
loaded nano micelles samples showed good hemocompati-
bility, and their water solubility and biocompatibility was
increased signicantly.110
Chavoshpour-Natanzi et al. prepared b-Lactoglobulin (BLG)
nanoparticles for the encapsulation of quercetin. The nano-
particles had a mean particle size of between 180–300 nm and
a loading efficiency (LE) of 13.9%. Protein nanoparticles could
be digested at different stages of the gastrointestinal tract,
depending on several factors including specicity of proteases
e.g. pepsin. This study suggested that nano formulation could
overcome BLG resistance to peptic digestion. Thus synthesised
BLG-quercetin nanoparticles could achieve controlled release of
quercetin under simulated conditions.93
The study performed by Simon et al. used harmless amphi-
philic polyoxazolines (POx) to encapsulate quercetin.96 They
produced mixed micelles, made of POx and phosphatidylcho-
line, using a thin lm and high-pressure homogeniser process.
The obtained nanomicelles that were about 20 nm in diameter
with a spherical shape and encapsulation efficiency of 94  4%.
They demonstrated improved cell viability and antioxidant
activity from these nanomicelles compared to quercetin alone.
Subsequently, this group synthesised quercetin encapsulated
lipid nanocapsules (LNC) using the same material POx.111 A


























































































View Article Onlinemixed micelles but implementing an additional short sonica-
tion step. The obtained LNC have a well-dened spherical shape
and a size of 30 nm.3.3 Enhancement of bioavailability
Jeyadevi et al. investigated the anti-arthritic activity of quercetin
with thioglycolic acid capped cadmium telluride quantum dots
(TGA-CdTe QDs) as nano carrier on adjuvant induced arthritic
Wistar rats.102 Fieen days aer adjuvant induction, arthritic
rats received QDs-quercetin complex orally at a dose of 0.2 and
0.4 mg kg1 daily for 3 weeks. The complex induced a signi-
cant reduction in inammation and improvement in cartilage
regeneration.
Aditya et al. reported a comparative study of solid lipid
nanoparticles (SLN), nanostructured lipid carriers (NLC), and
lipid nano emulsions (LNE) of quercetin.112 Encapsulation effi-
ciency (EE) of quercetin in these nanocarriers was above 90%.
Maximum bio-accessibility was observed with NLC and LNE
(W60%) compared to SLN (W35%) and free quercetin solution
(W7%).
Tran et al. developed a quercetin-containing self-
nanoemulsifying drug delivery system (Q-SNEDDS). Oil-in-
water nanoemulsions were formed to improve quercetin oral
bioavailability.98 Following oral administration of Q-SNEDDS in
rats (15 mg kg1), the maximum concentration (Cmax) of plasma
quercetin aer 24 h was 3.75  0.96 mg L1, increased by
approximately three-fold compared with the native quercetin
group (1.20  0.17 mg L1). The results suggested that Q-
SNEDDS can enhance the solubility and oral bioavailability of
quercetin. Collectively, Q-SNEDDS increased quercetin Cmax
and area under the concentration curve (AUC), from 6.7  1.4
L1 h1 to 14.0  2.8 L1 h1, without affecting its elimination
kinetics, suggesting that Q-SNEDDS improved quercetin
bioavailability by enhancing its absorption.
Dinesh Kumar et al. have also studied biodegradable poly-
meric nanoparticles for the effective delivery of quercetin. The
results suggest that optimised formulation of nanoparticles
could promote the controlled release and improve the physical
stability of quercetin.113
Lee et al. investigated the antioxidative and anti-
inammatory activities of quercetin-loaded silica nanoparticles
(QLSNs).94 QLSNs were synthesised using an oil-in-water micro-
emulsion method. The nanoparticles showed comparable cell
viability to that of the free quercetin, while the amounts of
proinammatory cytokines produced by macrophages, such as
TNF-kB, IL-6, and IL-1b, were signicantly reduced.
Caddeo et al. prepared cross-linked chitosan liposomes of
quercetin and conrmed that the system had acid resistance
and promoted the release under alkaline conditions.114 In
addition, Hao et al. proposed a facile electrostatic deposition
method to prepare quercetin nanoliposomes coated with chi-
tosan.115 The obtained Q-NPs have high EE (71.14%) and the
storage stability and antioxidant activity was improved
compared with native quercetin.
Penalva et al. studied the use of zein nanoparticles as
a carrier for the oral delivery of quercetin. Quercetin and 2-© 2021 The Author(s). Published by the Royal Society of Chemistryhydroxypropyl-b-cyclodextrin were encapsulated together in
zein nanoparticles. They showed that nanoparticles provided
high and sustained levels of quercetin in plasma aer oral
administration. The Cmax of plasma quercetin was 176 13.4 mg
mL1. Themean values obtained for AUC and the half-life of the
terminal phase (t1/2) were 167  8.21 mg h mL1 and 0.60 
0.35 h, respectively. The mean residence time (MRT) was 1.60 
0.12 h, whereas the quercetin clearance and its volume of
distribution were calculated to be 30 mL h1 and 26 mL h1,
respectively. The relative oral bioavailability was calculated to
be about 60%.116 They further optimised the preparative process
of quercetin loaded casein nanoparticles and evaluated the
pharmacokinetics of the nanoparticles aer oral administration
to Wistar rats117 showing that the relative oral bioavailability of
quercetin in nanoparticles (close to 37%) was about 9-times
higher than the oral solution of quercetin in a mixture of PEG
400 and water. Another study by Li et al. also used zein and
soluble soybean polysaccharide (SSPS) nanoparticles. The EE of
quercetin was greatly improved to 82.5% and the photochem-
ical stability and 2,20-azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid (ABTS+) scavenging ability of quercetin in such
nanoparticles were signicantly enhanced.100
Pivetta et al. produced nanostructured lipid carriers to load
quercetin. Their results indicated that the nanoparticles
exhibited a low recrystallization index (13.03%) which is
important to obtain high entrapment efficiency (97.42%) and
avoid drug expulsion during the storage time.118 Furthermore,
in a reconstructed human skin model, it was observed that the
topical formulation of quercetin-NLC presented no phototoxic
potential. Therefore, this developed nanostructure is a vehicle
with potential for topical administration of quercetin.
Research by Gokhale et al. reported a quercetin loaded nano
emulsion (NE)-based gel for the effective of management RA.119
This study showed that quercetin-NE has no toxic effect on
synoviocytes and a strong inhibitory effect on LPS-induced TNF-
a production. It has also exhibited adequate rheological
behaviour with a good texture prole and improved drug
permeation compared to a free quercetin gel. In addition, the
gel was found to be non-irritating and inhibited the formation
of paw edema in rats induced by Freund's complete adjuvant
(CFA) over 24 hours. Another study performed by Ghatak and
Iyyaswami used casein particles to encapsulate quercetin to
improve its water solubility and bioavailability.101 A maximum
encapsulation yield of 97% could be achieved with the addition
of 0.5% (w/v) sodium caseinate, 0.1 M of calcium chloride, 0.5 M
of di potassium hydrogen phosphate, 0.1 mM CTAB and 1 M of
sodium citrate at a pH of 7.3.4 Regulation of release rate
Liu et al. studied the characterization and biodistribution of
quercetin-loaded cationic nanostructured lipid carriers (QR-
CNLC) in vivo. QR-CNLC nanoparticles were prepared by
emulsication at high temperature and subsequent solidica-
tion at low temperature.78 QR-CNLC exhibited an average
particle size of 126.6 nm and 89.3% entrapment efficiency. TheRSC Adv., 2021, 11, 7280–7293 | 7287
Table 2 A summary of anti-rheumatoid related nano formulation of quercetina
Type Nanocarrier Preparation method Antisolvent Size (nm) Aim Ref.
Nanoparticles — Syringe pump Deionised water 170 Improvement of
solubility
107
Nanoparticles Dietary ber Antisolvent precipitation Water <100 Improvement of
solubility
92











Antisolvent precipitation Acetone 185 Enhancement of
bioavailability
102
Nanoparticles Polycaprolactone Nano-precipitation Pluronic F127 213–257 Enhancement of
bioavailability
113










Simple coacervation Water 200 Enhancement of
bioavailability
117
Nanoparticles Natural lipids Emulsion and sonication Pluronic F68 130 Enhancement of
bioavailability
118
Nanoparticles Zein, SSPS Antisolvent precipitation — 200 Enhancement of
bioavailability
100
Nanoparticles Casein Emulsion Ethanol 114.3–482.1 Enhancement of
bioavailability
101
Nanoparticles Mesoporous hydroxyapatite Magnetic stirring Deionised water 169–179 Regulation of release
rate
122
Nanoparticles Lecithin, chitosan Organic solvent injection Ethanol 95 Changes of
administration mode
123





Water 215 Changes of
administration mode
124
Nanoparticles Mesoporous silica Impregnation and magnetic
stirring
Methanol 200–300 Changes of
administration mode
95
Nanomicelles Amphiphilic chitosan Graing deoxycholic acid, N-
acetyl-L-cysteine





Thin lm and high pressure
homogeniser





Thin lm and high pressure
homogeniser process
Acetonitrile 30 Improvement of
solubility
111
Nanomicelles Pluronic P123/Poloxamer 188 Film dispersion Tween80 — Regulation of release
rate
121
Nanomicelles Amphiphilic chitosan Self assembly Deionised water 140–600 Regulation of release
rate
97










Nanoliposomes GMS, MCT, soy lecithin Emulsifying and solidifying Transcutol 118–135 Regulation of release
rate
78
Nanoliposomes DPPC, Cremophor® EL Magnetic stirring Alcohol 179 Changes of
administration mode
99

















Nanosuspensions — Evaporative precipitation Hexane 220 106



























































































Table 2 (Contd. )
Type Nanocarrier Preparation method Antisolvent Size (nm) Aim Ref.
Improvement of
solubility





Nanocapsules Lipid Magnetic stirring Milli Q water 26 Changes of
administration mode
99


























































































View Article Onlineresults demonstrated that QR-CNLC offered slower release
compared with quercetin solution in vitro.
Mohan et al. reported on TiO2 nanotubes that were loaded
initially with quercetin (TNTQ) and then additionally with chi-
tosan coated on the top of the quercetin (TNTQC) to various
thicknesses. The drug release of TNTQ and TNTQC were studied
in Hanks' solution for 192 hours. The results showed that the
release of drug into the local environment during that duration
was constant and the local concentration of the drug could be
controlled and tuned by controlling the thickness of the chito-
san (0.6, 1 and 3 mm).120
Zong et al. studied in vitro release of quercetin-loaded mixed
micelles composed of Pluronic P123/Poloxamer 188, and their
pharmacokinetics in rat.121 The results indicated that quercetin-
loaded mixed micelles have high entrapment efficiency and
loading efficiency which could improve the release behaviour in
vitro. The nano formulation of quercetin also prolonged the
circulation time of quercetin and signicantly enhanced the
bioavailability of quercetin. Hui et al. prepared and charac-
terised amphiphilic chitosan/quercetin nano micelles (ACS-
QNMs) using a novel amphiphilic chitosan (ACS).97 ACS has
deoxycholic acid (DA) as the hydrophobic group and n-acetyl-L-
cysteine (NAC) as the hydrophilic group. The results showed
that quercetin could be released in vivo and was stable when
stored at room temperature aer being embedded in nano
micelles.
Zhao et al. prepared a new nanodrug delivery system (quer-
cetin@mesoporous hydroxyapatite, QUE@MHAs) and investi-
gated its release in vitro.122 The results showed that QUE@MHAs
have good stability and a slow drug release rate.3.5 Transdermal administration
Quercetin is a avonoid with signicant antioxidant and anti-
inammatory activities and can be considered as a potential
topical drug for skin. Nevertheless, it suffers from poor water
solubility and consequently topical inactivity. To enhance its
transdermal absorption, a number of different nano formula-
tions of quercetin have been studied, including liposomes,
nanoparticles, micelles, and solid lipid nanoparticles.
Tan Qi studied the preparation and evaluation of quercetin-
loaded lecithin–chitosan nanoparticles for topical delivery.
Quercetin nanoparticles were prepared using organic solvent
injection. The results demonstrated that the nanoparticles© 2021 The Author(s). Published by the Royal Society of Chemistrycould clearly increase the amount of drug retention in especially
in the epidermis and also in the dermis, and further enhance
antioxidation and anti-inammatory effects.123
Guo et al. evaluated the potential of quercetin-loaded
nanostructured lipid carriers (QT-NLCs) as a topical delivery
system.124 The nanoparticles were prepared by the method of
emulsion evaporation–solidication at low temperature. The
results showed that QT-NLCs could promote the permeation of
quercetin, increase the amount of quercetin retention in
epidermis and dermis, and enhance the effect of anti-oxidation
and anti-inammation exerted by quercetin.
Sapino et al. evaluated the potential of aminopropyl func-
tionalised mesoporous silica nanoparticles (NH2-MSN) as
topical carrier system for quercetin delivery. The silica nano-
particle vehicle prevented UV-induced degradation of quercetin
over time, which showed positive effect on photostability of
quercetin. Epidermal accumulation and transdermal perme-
ation were evaluated ex vivo using porcine skin mounted on
Franz diffusion cells. The inclusion complexation with the
inorganic nanoparticles increased the penetration of quercetin
into the skin aer 24 hours post-application without trans-
dermal delivery.95
Hatahet et al. tested three approaches to improve quercetin
delivery to skin, including liposomes, lipid nanocapsules (LNC)
and smartCrystals®.99 They showed that compared to liposome
(0.56 mgmL1), quercetin smartCrystals® and LNC had a better
drug loading with 14.4 mgmL1 and 10.8 mgmL1 respectively.
SmartCrystals® and LNC demonstrated different skin penetra-
tion behaviours. Only LNC allow quercetin to be delivered to
viable epidermis that holds potential for treatment of skin
inammatory disorders.
In conclusion, quercetin is not only an important drug
source for oral administration but can also be used as a trans-
dermal absorbent by employing nanotechnology to enhance its
transdermal absorption capacity. It can be seen from all above
reports that different materials and forms of nano encapsula-
tion can have many positive effects on quercetin anti-
rheumatoid applications. Nano formulation has signicantly
improved the solubility and bioavailability of native quercetin,
and at the same time avoiding its shortcomings. The anti-
rheumatoid related nano formulations of quercetin are sum-


























































































View Article Online4 Conclusions and future perspective
Rheumatoid arthritis is a common worldwide public health
problem.125 It is in the top ten of the world's disease spectrum
and is also one of the diseases that seriously affect human
physical and mental health, with high rates of disability and
death. The pathogenesis of RA is very complex and has not been
fully elucidated. RA can be managed through conventional treat-
ments, but more attention has recently been paid to the treatment
of RA by natural active ingredients from medicinal plants,
including food plants, because of their safety and efficacy. In
recent years, the consumption of plant-based medicines and other
botanicals has increased. According to an estimate of World
Health Organization (WHO), nearly 80% of the populations of
developing countries rely on traditional medicines.126
As a plant derivedmedicine, quercetin is a striking candidate
for use in arthritic therapy.126 As summarised above, there are
many reports on the effects of quercetin on RA. It has been
conrmed that quercetin has signicant anti-inammatory and
analgesic effects in vivo and in vitro and furthermore, quercetin
and its derivatives also have signicant antioxidant effects,
which is one of the possible reasons for their signicant anti-
rheumatic properties.20 At the same time, it is reported that
quercetin is mostly well tolerated and safe to use. Doses up to
1000mg each day for several months have not produced adverse
effects on blood parameters, and liver, and kidney function. As
a potential bioavailability enhancer for active pharmaceutical
ingredients, quercetin can also be used as one of the options in
combination therapy for RA.65 Moreover, it has been shown that
with the application of nano formulations, quercetin has not
only improved oral bioavailability, but also can be used for
external transdermal use, which provides a new reference for
the treatment of RA.
Move rover, Susanne Andres et al. reviewed the safety aspects
of quercetin as a dietary supplement. It showed that based on
animal studies, some possible critical safety aspects of quer-
cetin could be identied such as to enhance nephrotoxic effects
in the predamaged kidney or to promote tumour development
especially in estrogen-dependent cancer.127 Furthermore, when
quercetin interacts with some drugs, the bioavailability of may be
altered. Therefore, it suggests that, like any potential drug or active
ingredient, a very in-depth study on its safety and applicability
should be conducted before clinical application. Future clinical
studies are needed to verify the safety and efficacy of nano
formulated quercetin as a new RA treatment medicine. Future
clinical studies are needed to verify the safety and efficacy of Nano
formulated quercetin as a new RA treatment medicine.
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Ascêncio, S. D. Ascêncio and D. T. d. O. Martins, J.
Ethnopharmacol., 2014, 154, 319–329.
48 Y. Luan and R. Sun, Chin. J. Pharmacovigil., 2014, 11, 219–
221.
49 A. Gong, Y. Ouyang, X. Zhang, X. Zhao and M. Wu, World
Lat. Med. Info., 2015, 15, 25–27.
50 K. McNamee, R. Williams and M. Seed, Eur. J. Pharmacol.,
2015, 759, 278–286.© 2021 The Author(s). Published by the Royal Society of Chemistry51 K. Fan, J. Wu, Y. Li and T. Wang, Pract. Pharm. Clin. Rem.,
2018, 21, 709–713.
52 T. Guardia, A. E. Rotelli, A. r. O. Juarez and L. E. Pelzer,
Farmaco, 2001, 56, 683–687.
53 M. Mamani-Matsuda, T. Kauss, A. Al-Kharrat, J. Rambert,
F. Fawaz, D. Thiolat, D. Moynet, S. Coves, D. Malvy and
M. D. Mossalayi, Biochem. Pharmacol., 2006, 72, 1304–1310.
54 C. Gardi, K. Bauerova, B. Stringa, V. Kuncirova, L. Slovak,
S. Ponist, F. Dra, L. Bezakova, I. Tedesco, A. Acquaviva,
S. Bilotto and G. L. Russo, Arch. Biochem. Biophys., 2015,
583, 150–157.
55 N. Haleagrahara, S. Miranda-Hernandez, M. A. Alim,
L. Hayes, G. Bird and N. Ketheesan, Biomed.
Pharmacother., 2017, 90, 38–46.
56 Y. Yang, X. Zhang, M. Xu, X. Wu, F. Zhao and C. Zhao, Int.
Immunopharmacol., 2018, 54, 153–162.
57 Y.-q. Wang, S.-f. Chen and Y. Mei, Immunol. J., 2019, 35,
485–491.
58 Q.-y. Jia, Y.-j. Wang, Q.-q. Liang and Q. Shi, Chin. J.
Osteoporosis, 2019, 25, 738–741.
59 Q.-y. Jia, Y.-j. Wang, Q.-q. Liang and Q. Shi, J. Osteoporosis,
2018, 24, 1175–1179.
60 C. F. S. Guazelli, L. Staurengo-Ferrari, A. C. Zarpelon,
F. A. Pinho-Ribeiro, K. W. Ruiz-Miyazawa, F. Vicentini,
J. A. Vignoli, D. Camilios-Neto, S. R. Georgetti,
M. M. Baracat, R. Casagrande and W. A. Verri Jr, Biomed.
Pharmacother., 2018, 102, 175–184.
61 J.-J. Ji, Y. Lin, S.-S. Huang, H.-L. Zhang, Y.-P. Diao and K. Li,
Afr. J. Tradit., Complementary Altern. Med., 2013, 10, 418–
421.
62 P. Xiao, P. Wang, X. Zhu, J.-P. Sun and X.-j. Wu, Chin. J. Exp.
Surg., 2016, 33, 2378–2380.
63 M. K. Pandey, S. C. Gupta, D. Karelia, P. J. Gilhooley,
M. Shakibaei and B. B. Aggarwal, Biotechnol. Adv., 2018,
36, 1633–1648.
64 S. S. Laev and N. F. Salakhutdinov, Bioorg. Med. Chem.,
2015, 23, 3059–3080.
65 A. Ajazuddin, A. Alexander, A. Qureshi, L. Kumari,
P. Vaishnav, M. Sharma, S. Saraf and S. Saraf, Fitoterapia,
2014, 97, 1–14.
66 D. D. Bandawane, S. Beautikumari, S. S. Gate and
A. N. Patel, Biomed. Aging Pathol., 2014, 4, 105–115.
67 X. Han, D. Su, X. Xian, M. Zhou, X. Li, J. Huang, J. Wang and
H. Gao, J. Ethnopharmacol., 2016, 194, 228–235.
68 A. Tanwar, R. Chawla, M. M. Ansari, S. A. Neha, P. Thakur,
A. S. Chakotiya, R. Goel, H. Ojha, M. Asif, M. Basu, R. Arora
and H. A. Khan, Biomed. Pharmacother., 2017, 87, 92–101.
69 R. Adhikary, S. Sultana and B. Bishayi, J. Ethnopharmacol.,
2018, 210, 209–222.
70 G.-S. Zou, S.-J. Li, S.-l. Zheng, X. Pan and Z.-p. Huang, J.
Taiwan Inst. Chem. Eng., 2018, 93, 54–62.
71 H. Xiong, X. Ding, H. Wang, H. Jiang, X. Wu, C. Tu, C. Wu,
Y. Pi, G. Yang, Z. Zhao and Z. Mei, Phytomedicine, 2019, 57,
271–281.
72 A. J. Day, Y. Bao, M. R. A. Morgan and G. Williamson, Free


























































































View Article Online73 S. de Pascual-Teresa, K. L. Johnston, M. S. DuPont,
K. A. O'Leary, P. W. Needs, L. M. Morgan, M. N. Clifford,
Y. Bao and G. Williamson, J. Nutr., 2004, 134, 552–557.
74 D.-y. Ning, Q.-y. Zhang, X.-l. Tan and X.-x. Huang, Sci.
Technol. Innov., 2019, 41–42.
75 X. Lu and C. Jiang, Her. Med., 2019, 38, 921–926.
76 Y. Guo and R. S. Bruno, J. Nutr. Biochem., 2015, 26, 201–210.
77 K. Janakiraman, V. Krishnaswami, V. Rajendran, S. Natesan
and R. Kandasamy, Mater. Today Commun., 2018, 17, 200–
213.
78 L. Liu, Y. Tang, C. Gao, Y. Li, S. Chen, T. Xiong, J. Li, M. Du,
Z. Gong, H. Chen, L. Liu and P. Yao, Colloids Surf., B, 2014,
115, 125–131.
79 X. R. Feng, W. G. Xu, Z. M. Li, W. T. Song, J. X. Ding and
X. S. Chen, Adv. Sci., 2019, 6, 1900101.
80 Y. Davatgaran-Taghipour, S. Masoomzadeh, M. H. Farzaei,
R. Bahramsoltani, Z. Karimi-Soureh, R. Rahimi and
M. Abdollahi, Int. J. Nanomed., 2017, 12, 2689–2702.
81 S. Khogta, J. Patel, K. Barve and V. Londhe, J. Herb. Med.,
2019, 100300, DOI: 10.1016/j.hermed.2019.100300.
82 T. Y. Forbes-Hernández, J. Berry Res., 2020, 10, 45–60.
83 S. Z. Moradi, S. Momtaz, Z. Bayrami, M. H. Farzaei and
M. Abdollahi, Front. Bioeng. Biotechnol., 2020, 8, 238.
84 A. Vaiserman, A. Koliada, A. Zayachkivska and O. Lushchak,
Front. Bioeng. Biotechnol., 2020, 7, 447.
85 P. Aiello, S. Consalvi, G. Poce, A. Raguzzini, E. Toti,
M. Palmery, M. Biava, M. Bernardi, M. A. Kamal, G. Perry
and I. Peluso, Semin. Cancer Biol., 2019, DOI: 10.1016/
j.semcancer.2019.08.029.
86 N. B. Feng, M. D. Yang, X. R. Feng, Y. N. Wang, F. Chang
and J. X. Ding, ACS Biomater. Sci. Eng., 2018, 4, 4154–4162.
87 Q. Wang and Y.-M. Chao, J. Biomed. Res., 2018, 32, 91–106.
88 H. Alshaker, Q. Wang, S. Srivats, Y. Chao, C. Cooper and
D. Pchejetski, Breast Cancer Res. Treat., 2017, 165, 531–543.
89 Q. Wang, H. Alshaker, T. Böhler, S. Srivats, Y. Chao,
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